Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study

Updated overall survival and ctDNA analysis in patients with EGFR T790M-positive advanced non-small cell lung cancer treated with lazertinib in the phase 1/2 LASER201 study

Abstract Background Lazertinib is a potent, irreversible, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with significant efficacy in patients with EGFR T790M-mutated non-small cell lung cancer (NSCLC). This is the final overall survival (OS) report from the...

Full description

Bibliographic Details
Main Authors: Ji-Youn Han, Myung-Ju Ahn, Ki Hyeong Lee, Yun-Gyoo Lee, Dong-Wan Kim, Young Joo Min, Sang-We Kim, Eun Kyung Cho, Joo-Hang Kim, Gyeong-Won Lee, Sung Sook Lee, Na Mi Lee, Hyun Woo Jang, Heewon Han, Hyejoo Park, Jieon Lee, Byoung Chul Cho
Format: Article
Language:English
Published: BMC 2024-10-01
Series:BMC Medicine
Subjects:
ctDNA
Lazertinib
NSCLC
TKI
Overall survival
Online Access:https://doi.org/10.1186/s12916-024-03620-8

Internet

https://doi.org/10.1186/s12916-024-03620-8

Similar Items